SAN DIEGO --(BUSINESS WIRE)--Apr. 14, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that since the Company began offering SARS-CoV-2 testing services in June 2020 , it has now received more than 350,000 samples for testing.
Molecular assay provides highly sensitive, quantitative method to identify cancer involving the central nervous system, inform treatment decisions, and monitor therapy response SAN DIEGO --(BUSINESS WIRE)--Apr. 21, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic
Foundation offers COVID-19 testing and support to more than 2.1 million students as part of campus health services SAN DIEGO --(BUSINESS WIRE)--Apr. 28, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, has partnered with the Foundation
SAN DIEGO --(BUSINESS WIRE)--May 5, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it will release financial results for the three months ended March 31, 2021 after the market closes on Wednesday, May 12, 2021 .
Revenues of $17.8 million were driven by RT-PCR COVID-19 testing Initiated full commercial launch of CNSide™ cerebrospinal fluid assay for diagnosing and managing patients with metastatic cancer involving the central nervous system Received approximately 390,000 COVID-19 samples since June 2020
SAN DIEGO --(BUSINESS WIRE)--Jun. 2, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 144,580 shares of its common stock to eighteen new employees.
SAN DIEGO --(BUSINESS WIRE)--Jun. 3, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall , President and CEO, will present at the LD Micro Virtual Invitational XI Conference on June 9, 2021 at 3:00 p.m.
Integrated solution incorporates testing protocols and real-time test results to help ensure safer, healthier campuses, healthcare facilities and other venues SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2021-- Biocept (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and
SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2021-- Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that it has received more than 420,000 samples for SARS-CoV-2 testing since launching this service in June 2020 .
SAN DIEGO --(BUSINESS WIRE)--Jun. 22, 2021-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced a collaboration with Quest Diagnostics (NYSE: DGX) to provide laboratory testing services to Quest patients for its Target Selector™
